Advanced Enzyme Technologies (540025) Stock Overview
Engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
540025 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Advanced Enzyme Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹325.10 |
| 52 Week High | ₹571.15 |
| 52 Week Low | ₹257.85 |
| Beta | 0.40 |
| 1 Month Change | 12.57% |
| 3 Month Change | 21.83% |
| 1 Year Change | -14.93% |
| 3 Year Change | 16.31% |
| 5 Year Change | 93.40% |
| Change since IPO | 37.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 540025 | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | 6.8% | 0.4% | 2.3% |
| 1Y | -14.9% | 5.5% | 2.9% |
Return vs Industry: 540025 underperformed the Indian Chemicals industry which returned 5.5% over the past year.
Return vs Market: 540025 underperformed the Indian Market which returned 2.9% over the past year.
Price Volatility
| 540025 volatility | |
|---|---|
| 540025 Average Weekly Movement | 5.0% |
| Chemicals Industry Average Movement | 6.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: 540025 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 540025's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 323 | Mukund Kabra | www.advancedenzymes.com |
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications, biofuels, and bio-catalysis. It provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids.
Advanced Enzyme Technologies Limited Fundamentals Summary
| 540025 fundamental statistics | |
|---|---|
| Market cap | ₹36.37b |
| Earnings (TTM) | ₹1.31b |
| Revenue (TTM) | ₹6.37b |
Is 540025 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 540025 income statement (TTM) | |
|---|---|
| Revenue | ₹6.37b |
| Cost of Revenue | ₹1.52b |
| Gross Profit | ₹4.85b |
| Other Expenses | ₹3.54b |
| Earnings | ₹1.31b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.72 |
| Gross Margin | 76.16% |
| Net Profit Margin | 20.59% |
| Debt/Equity Ratio | 1.5% |
How did 540025 perform over the long term?
See historical performance and comparisonDividends
Does 540025 pay a reliable dividends?
See 540025 dividend history and benchmarks| Advanced Enzyme Technologies dividend dates | |
|---|---|
| Ex Dividend Date | Jul 23 2025 |
| Dividend Pay Date | Aug 29 2025 |
| Days until Ex dividend | 40 days |
| Days until Dividend pay date | 77 days |
Does 540025 pay a reliable dividends?
See 540025 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/12 22:26 |
| End of Day Share Price | 2025/06/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Advanced Enzyme Technologies Limited is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| null null | DBS Bank Ltd |
| Dhananjay Sinha | Emkay Global Financial Services Ltd. |